CLINICAL ROLE -
Clinical Overview: Tildrakizumab-asmn (Ilumya) for Plaque Psoriasis
Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.
Oncology Overview: Investigational Imlunestrant for Breast Cancer, Endometrial Cancer
Imlunestrant is currently under investigation as monotherapy or in combination with other anticancer therapies for patients with estrogen receptor-positive, locally advanced or metastatic breast cancer and endometrial cancer.
Clinical Overview: Cabenuva for HIV
Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.
Clinical Overview: Cabenuva for Adults with HIV-1
The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.
2 Commerce Drive Cranbury, NJ 08512